ARCH Healthcare Fund

ARCH focuses on early-stage healthcare companies, typically seed and Series A, spanning digital health, medical devices, biotech tools, and healthcare services. The firm uses a distributed office model rather than a single headquarters, placing investing professionals in multiple U.S. cities alongside Singapore, Amsterdam, and Vilnius. This structure is designed to surface deals across fragmented health-tech markets and to support portfolio companies with local knowledge of regulatory and reimbursement landscapes.

Most health-tech venture firms operate from one or two U.S. offices, often Boston or San Francisco. ARCH maintains offices in at least 12 cities across four countries, including Singapore and multiple European locations. This distributed design is unusual and suggests the firm underwrites opportunities using principals embedded in local ecosystems rather than flying in from a central hub for diligence.

ARCH's office footprint in Singapore and Amsterdam indicates direct non-U.S. investment activity, not just a base for helping U.S. portfolio companies expand overseas. The Singapore office likely covers Southeast Asian health-tech, while Amsterdam and Vilnius provide access to European digital health and medtech startups. The exact geographic split of deployed capital is not publicly disclosed.

ARCH does not publicly list its investment committee members or managing partners. The firm does not maintain a visible LinkedIn page or detailed team section on its website, and no principal names appear in standard venture capital databases as of this profile publication. The decision-making structure — whether centralized or distributed across office leads — is not verifiable from public sources.

Whether the Singapore, Amsterdam, and Vilnius offices operate as independent investment nodes with their own allocations or as sourcing outposts feeding a central U.S. investment committee is unclear from public records. The model could range from a unified global fund to a network of regionally autonomous vehicles. This structural ambiguity is one of the defining unknowns for an allocator evaluating the firm.